Literature DB >> 29997931

Long-term outcome after resection for recurrent oesophageal cancer.

Fumihiko Kato1, Satoko Monma2, Kazuo Koyanagi1, Jun Kanamori1, Hiroyuki Daiko1, Hiroyasu Igaki3, Yuji Tachimori4.   

Abstract

BACKGROUND: The efficacy of surgical resection for lymph node (LN) or distant recurrence of oesophageal cancer has not been sufficiently investigated. The objective of this study was to reveal appropriate indications for a surgical approach.
METHODS: A total of 42 patients who underwent resection for recurrent or residual oesophageal squamous cell carcinoma after surgery or definitive chemoradiotherapy (dCRT) between April 2004 and August 2016 were identified. These resections did not include salvage oesophagectomy. The long-term outcomes of these patients were retrospectively analysed.
RESULTS: Thirty-three patients underwent LN resection, 6 patients underwent lung resection, and 3 patients underwent resection for other recurrent tumours. The 5-year overall survival (OS) of patients who underwent salvage abdominal lymphadenectomy after dCRT was significantly better than that of patients who underwent salvage cervical or mediastinal lymphadenectomy (46.9% vs. 0.0%, P=0.006). The 5-year OS of patients who underwent salvage resection for LNs outside the radiation field was significantly better than that of patients who underwent resection inside the radiation field (47.6% vs. 8.9%, P=0.027). The 5-year OS of patients who underwent salvage resection for recurrent LNs was significantly better than that of patients who underwent salvage resection for residual LNs (21.7% vs. 0.0%, P<0.001). Among the 42 patients, 9 survived more than 3 years: 4 after salvage abdominal lymphadenectomy, 3 after resection for solitary lung recurrence, and 2 others.
CONCLUSIONS: The use of the appropriate surgical approach might improve the prognosis of patients with abdominal LN recurrence, LN recurrence outside the radiation field, or a solitary lung recurrence of oesophageal cancer.

Entities:  

Keywords:  Oesophageal cancer; chemoradiotherapy (CRT); lymphadenectomy; recurrence

Year:  2018        PMID: 29997931      PMCID: PMC6006052          DOI: 10.21037/jtd.2018.05.17

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  19 in total

1.  Salvage lymphadenectomy versus salvage radiotherapy/chemoradiotherapy for recurrence in cervical lymph node after curative resection of esophageal squamous cell carcinoma.

Authors:  Xiao Ma; Kuaile Zhao; Wei Guo; Su Yang; Xiaoli Zhu; Jiaqing Xiang; Yawei Zhang; Hecheng Li
Journal:  Ann Surg Oncol       Date:  2014-08-26       Impact factor: 5.344

2.  Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer.

Authors:  M Yano; K Takachi; Y Doki; I Miyashiro; K Kishi; S Noura; H Eguchi; T Yamada; M Ohue; H Ohigashi; Y Sasaki; O Ishikawa; T Matsunaga; S Imaoka
Journal:  Dis Esophagus       Date:  2006       Impact factor: 3.429

3.  Operative treatment for metachronous pulmonary metastasis from esophageal carcinoma.

Authors:  Hiroshi Ichikawa; Shin-ichi Kosugi; Satoru Nakagawa; Tatsuo Kanda; Masanori Tsuchida; Teruaki Koike; Otsuo Tanaka; Katsuyoshi Hatakeyama
Journal:  Surgery       Date:  2010-09-06       Impact factor: 3.982

4.  Outcome and treatment strategy for mid- and lower-thoracic esophageal cancer recurring locally in the lymph nodes of the neck.

Authors:  Satoru Motoyama; Michihiko Kitamura; Reijiro Saito; Kiyotomi Maruyama; Manabu Okuyama; Jun-ichi Ogawa
Journal:  World J Surg       Date:  2006-02       Impact factor: 3.352

5.  Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).

Authors:  Ken Kato; Kei Muro; Keiko Minashi; Atsushi Ohtsu; Satoshi Ishikura; Narikazu Boku; Hiroya Takiuchi; Yoshito Komatsu; Yoshinori Miyata; Haruhiko Fukuda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-06       Impact factor: 7.038

6.  Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option?

Authors:  Sheraz Markar; Caroline Gronnier; Alain Duhamel; Arnaud Pasquer; Jérémie Théreaux; Mael Chalret du Rieu; Jérémie H Lefevre; Kathleen Turner; Guillaume Luc; Christophe Mariette
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

7.  Salvage lymphadenectomy for recurrent esophageal cancer after chemoradiotherapy.

Authors:  Masanobu Nakajima; Yasushi Domeki; Hitoshi Satomura; Masakazu Takahashi; Akira Sugawara; Hiroto Muroi; Kinro Sasaki; Satoru Yamaguchi; Tatsuya Miyazaki; Hiroyuki Kuwano; Hiroyuki Kato
Journal:  Int Surg       Date:  2014 Jul-Aug

8.  Salvage lymphadenectomy of the right recurrent nerve node with tracheal involvement after definitive chemoradiation therapy for esophageal squamous cell carcinoma: report of two cases.

Authors:  Yuichiro Doki; Takushi Yasuda; Hiroshi Miyata; Yoshiyuki Fujiwara; Shuji Takiguchi; Makoto Yamasaki; Yoichi Makari; Jin Matsuyama; Takeshi Masuoka; Morito Monden
Journal:  Surg Today       Date:  2007-06-26       Impact factor: 2.549

9.  Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases.

Authors:  Satoshi Shiono; Masafumi Kawamura; Toru Sato; Ken Nakagawa; Jun Nakajima; Ichiro Yoshino; Norihiko Ikeda; Hirotoshi Horio; Hirohiko Akiyama; Koichi Kobayashi
Journal:  J Thorac Oncol       Date:  2008-09       Impact factor: 15.609

10.  Metastasis of esophageal carcinoma to the brain.

Authors:  Jeffrey S Weinberg; Dima Suki; Fadi Hanbali; Zvi R Cohen; Renato Lenzi; Raymond Sawaya
Journal:  Cancer       Date:  2003-11-01       Impact factor: 6.860

View more
  4 in total

1.  Association Between Multiple Lines of Active Therapy and Prognosis in Esophageal Squamous Cell Carcinoma.

Authors:  Ying Yang; Jun Jia; Zhiwei Sun; Chuanling Liu; Yanjie Xiao; Jing Yu; Feng Du; Xiaodong Zhang
Journal:  Cancer Manag Res       Date:  2020-03-24       Impact factor: 3.989

2.  Clinical outcomes of surgical resection for recurrent lesion after curative esophagectomy for esophageal squamous cell carcinoma: a nationwide, large-scale retrospective study.

Authors:  Kensuke Kudou; Hiroshi Saeki; Yuichiro Nakashima; Yasue Kimura; Eiji Oki; Masaki Mori; Mototsugu Shimokawa; Yoshihiro Kakeji; Yasushi Toh; Yuichiro Doki; Hisahiro Matsubara
Journal:  Esophagus       Date:  2021-09-12       Impact factor: 4.230

3.  Successful multidisciplinary treatment including repeated metastasectomy for recurrent squamous cell esophageal carcinoma: a case report.

Authors:  Kosuke Hirose; Hiroshi Saeki; Yuichiro Nakashima; Tomohiro Kamori; Yoshiaki Fujimoto; Tetsuro Kawazoe; Hiroya Matsuoka; Yasuhiro Haruta; Shun Sasaki; Tomoko Jogo; Qingjiang Hu; Yasuo Tsuda; Koji Ando; Eiji Oki; Ryuzo Hiratsuka; Yoshinao Oda; Masaki Mori
Journal:  Surg Case Rep       Date:  2019-05-03

Review 4.  Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma.

Authors:  Koichi Yagi; Tetsuro Toriumi; Susumu Aikou; Hiroharu Yamashita; Yasuyuki Seto
Journal:  Ann Gastroenterol Surg       Date:  2021-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.